Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)

NCT07653503 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Cervical Carcinoma

Interventions

DRUG: Nivolumab

Sponsor

University Medical Center Groningen